Compare PEW & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEW | ELTX |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 63.3M |
| IPO Year | 2025 | 2014 |
| Metric | PEW | ELTX |
|---|---|---|
| Price | $2.31 | $2.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.75 | ★ $18.00 |
| AVG Volume (30 Days) | 237.9K | ★ 266.2K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,449,000.00 | $2,301,000.00 |
| Revenue This Year | $5.25 | N/A |
| Revenue Next Year | $7.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.57 | N/A |
| 52 Week Low | $2.22 | $2.34 |
| 52 Week High | $6.76 | $16.00 |
| Indicator | PEW | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 24.01 |
| Support Level | $2.25 | N/A |
| Resistance Level | $2.75 | $3.32 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 24.37 | 1.09 |
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition and related accessories. The Company's firearm products are ordered and paid for by customers online through the Company's eCommerce site and mobile app and are delivered to them on-premises through their choice of federal firearm licensed dealers nationwide. The Company's network of localized firearm dealers perform background checks on firearms purchasers and complete sales forms as mandated by federal and state firearm regulations.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.